Stockwatch: UniQure's guile and the dubious promise of gene therapy

After last week's headline-grabbing deal between Bristol Myers Squibb (BMS) and Dutch gene therapy company uniQure (scripintelligence.com, 6 April 2015), who would have thought that events in Europe might by the end of the week spell the demise of uniQure's gene therapy platform?

Certainly not the business development group at BMS, who stumped up a $127m investment in uniQure and should now be dreading their annual performance reviews of a deal where due diligence seems to have been lacking. Nor the poor investors who shelled out $88.5m in the uniQure fund-raising, which for some reason followed the BMS deal announcement with great haste